Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
PROACT 3: Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
Massachusetts General Hospital
500 participants
Oct 15, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to evaluate whether disclosure of a polygenic risk score for coronary artery disease (CAD PRS) influences cardiovascular health and risk factor modification over one year among adults aged 30-75 years in the Mass General Brigham primary care network who are not currently taking LDL cholesterol-lowering medications.
Eligibility
Inclusion Criteria2
- Current age 30-75 years
- Established primary care at Mass General Brigham with at least one visit in the last 2 years
Exclusion Criteria1
- \- Currently taking LDL cholesterol- lowering medications, including statins
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants receive their CAD PRS results as soon as they are available after genotyping.
Participants receive their CAD PRS results after completion of the 12 month follow up period.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07087431